Citations

Clear

3138 citation(s) found for "Smith, AM".

Use and safety of corticosteroid injections in joints and musculoskeletal soft tissue: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, the American Society of Interventional Pain Physici
Benzon, Honorio T. , Provenzano, David , Nagpal, Ameet , Souza, Dmitri , Eckmann, Maxim , Nelson, Ariana M. , Mina, Maged, Elmofty, Dalia , Pino, Carlos A. , Rana, Maunak V., Shah, Shalini , Stout, Alison , Smith, Elizabeth Reichert , Hirsch, Joshua A , Schneider, Byron J. , Manchikanti, Laxmaiah , Maus, Timothy P. , Rivera, Jessica , FitzGerald, John , Provenzano, David Anthony , Chadwick, Andrea , Doshi, Tina L , Pino, Carlos A , Shankar, Hariharan , Cohen, Steven P , Narouze, Samer , Shanthanna, Harsha , Hunt, Christine , Benzon, Honorio T , Nagpal, Ameet S , FitzGerald, John D , Nelson, Ariana M , Abd-Elsayed, Alaa A , Doshi, Tina L , Shankar, Hariharan , Smith, Elizabeth, Abdi, Salahadin , Cohen, Steven P. , Narouze, Samer , Shanthanna, Harsha , Wasan, Ajay D. , Hoang, Thanh D , Rivera, Jessica

Mayo Clinic

Regional Anesthesia & Pain Medicine | February 27, 2025 | Volume: 51 | Issue: 7 | Pages: 746-773

10.1136/rapm-2024-105656 | PMID 40015722 Get It

Background Intra-articular corticosteroid (IACS) injection and peri-articular corticosteroid injection are commonly used to treat musculoskeletal conditions. Results vary by musculoskeletal region, but most studies report short-term benefit with mixed results on long-term relief. Publications showed adverse events from single corticosteroid injections. Recommended effective doses were lower than those currently used by clinicians. Methods Development of the practice guideline for joint injections was approved by the Board of Directors of the American Society of Regional Anesthesia and Pain Medicine and the participating societies. A Corticosteroid Safety Work Group coordinated the development of three guidelines: peripheral nerve blocks and trigger points; joints; and neuraxial, facet, and sacroiliac joint injections. The topics included safety of the technique in relation to landmark-guided, ultrasound-guided, or radiology-aided injections; effect of the addition of the corticosteroid on the efficacy of the injectate; and adverse events related to the injection. Experts on the topics were assigned to extensively review the literature and initially develop consensus statements and recommendations. A modified version of the US Preventive Services Task Force grading of evidence and strength of recommendation was followed. A modified Delphi process was adhered to in arriving at a consensus. Results This guideline focuses on the safety and efficacy of corticosteroid joint injections for managing joint chronic pain in adults. The joints that were addressed included the shoulder, elbow, hand, wrist, hip, knee, and small joints of the hands and feet. All the statements and recommendations were approved by all participants and the Board of Directors of the participating societies after four rounds of discussion. There is little evidence to guide the selection of one corticosteroid over another. Ultrasound guidance increases the accuracy of injections and reduces procedural pain. A dose of 20 mg triamcinolone is as effective as 40 mg for both shoulder IACS and subacromial subdeltoid bursa corticosteroid injections. The commonly used dose for hip IACS is 40 mg triamcinolone or methylprednisolone. Triamcinolone 40 mg is as effective as 80 mg for knee IACS. Overall, IACS injections result in short-term pain relief from a few weeks to a few months. The adverse events include an increase in blood glucose, adrenal suppression, detrimental effect on cartilage lining the joint, reduction of bone mineral density, and postoperative joint infection. Conclusions In this practice guideline, we provided specific recommendations on the role of corticosteroids in joint, bursa, and peritendon injections for musculoskeletal pain.
Intracluster correlation coefficients from cluster randomized trials conducted within the NCI Community Oncology Research Program (NCORP)
Snavely, Anna C. , Lee, Ju-Whei, Pugh, Stephanie L. , Arnold, Kathryn B. , Smith, Sydney A. , Tan, Angelina D, Dockter, Travis , Zahrieh, David M. , Gunn, Heather J., Gunn, Heather , Barlow, William E. , Culakova, Eva , Kittel, Carol , Hanlon, Bret M. , Tan, Angelina D, Dressler, Emily V.

Mayo Clinic

JNCI Monographs | February 24, 2025 | Volume: 2025 | Issue: 68 | Pages: 65-72

10.1093/jncimonographs/lgae048 | PMID 39989039 Get It

Abstract The intracluster correlation coefficient (ICC) measures the correlation of observations within clusters and is a key parameter for power and sample size calculations for cluster randomized trials (CRTs). To facilitate the design of future CRTs within the National Cancer Institute Community Oncology Research Program (NCORP), all studies from the NCORP website were reviewed to identify completed CRTs. ICCs for primary and secondary outcomes (when available) were ascertained from these trials and summarized in this article as a resource for future trial development. Although ICCs are relatively small for many outcome cluster combinations, that is not always the case, so consideration should always be given to the specific outcome of interest, trial design, and type of cluster when estimating an ICC to facilitate trial development.
Guiding Principles for Data Sharing and Harmonization: Results of a Systematic Review and Modified Delphi From the Society of Critical Care Medicine Data Science Campaign
Armaignac, Donna Lee , Heavner, Smith F. , Rausen, Michelle , Zhang, Xiaohan Tanner , Al-Hakim, Tamara, Strekalova, Yulia Levites , Shah, Neel , Remy, Kenneth E. , Manion, Sean T. , Scruth, Elizabeth , Rincon, Teresa , Park, Soojin , Evans, Laura , Ozrazgat‐Baslanti, Tezcan , Murphy, David J. , Engel, Heidi J., Cobb, J. Perren , Clermont, Gilles , Park, Soojin , Laudański, Krzysztof , Haendel, Melissa , Kramer, Andrew A. , Herasevich, Vitaly , Sikora, Andrea , Khanna, Ashish K. , Zimmerman, Jerry J. , Reuter‐Rice, Karin

Mayo Clinic

Critical Care Medicine | February 21, 2025 | Volume: 53 | Issue: 3 | Pages: e619-e631

10.1097/ccm.0000000000006578 | PMID 39982146 Get It

OBJECTIVES: This study aimed to establish a set of guiding principles for data sharing and harmonization in critical care, focusing on the use of real-world data (RWD) and real-world evidence (RWE) to improve patient outcomes and research efficacy. The principles were developed through a systematic literature review and a modified Delphi process, with the goal of enhancing data accessibility, standardization, and interoperability across critical care settings. DATA SOURCES: Data sources included a comprehensive search of peer-reviewed literature, specifically studies related to the use of RWD and RWE in healthcare, guidelines, best practices, and recommendations on data sharing and harmonization. A total of 8150 articles were initially identified through databases such as MEDLINE and Web of Science, with 257 studies meeting inclusion criteria. STUDY SELECTION: Inclusion criteria focused on publications discussing health-related informatics, recommendations for RWD/RWE usage, data sharing, and harmonization principles. Exclusion criteria ruled out non-human studies, case studies, conference abstracts, and articles published before 2013, as well as those not available in English. DATA EXTRACTION: From the 257 selected studies, 322 statements were extracted. After removing irrelevant definitions and off-topic content, 232 statements underwent content validation and thematic analysis. These statements were then consolidated into 24 candidate guiding principles after rigorous review and consensus-building among the expert panel. DATA SYNTHESIS: A three-phase modified Delphi process was employed, involving a conceptualization group, a review group, and a Delphi group. In phase 1, experts identified key themes and search terms for the systematic review. Phase 2 involved validating and refining the prospective guiding principles, while phase 3 employed a Delphi panel to rate principles on acceptability, importance, and feasibility. This process resulted in 24 guiding principles, with high consensus achieved in rounds 2 and 3 on their relevance and applicability. CONCLUSIONS: The systematic review and Delphi process resulted in 24 guiding principles to improve data sharing and harmonization in critical care. These principles address challenges across the data lifecycle, including generation, storage, access, and usage of RWD and RWE. This framework is designed to promote more effective and equitable data practices, with relevance for the development of artificial intelligence-based decision support tools and clinical research. The principles are intended to guide the responsible use of data science in critical care, with emphasis on ethics and equity, while acknowledging the variability of resources across settings.
Development of a Core Critical Care Data Dictionary With Common Data Elements to Characterize Critical Illness and Injuries Using a Modified Delphi Method
Anderson, Wesley R., Heavner, Smith H., Al-Hakim, Tamara, Cruz‐Cano, Raul , Engel, Heidi J., Lamb, Keith, MacLaren, Robert , Rincon, Teresa , Sikora, Andrea, Tanner, Donna, Teeter, William , Wong, An-Kwok Ian , Zhang, Xiaohan Tanner , Zimmerman, Jerry J. , Kumar, Vishakha K. , Cobb, J. Perren, Laudański, Krzysztof , Murphy, David J., Anderson, Wesley, Heavner, Smith H., Kamaleswaran, Rishikesan , Badawi, Omar , Grunwell, Jocelyn R. , Herasevich, Vitaly , Khanna, Ashish K. , Sanchez-Pinto, Lazaro Nelson , Sikora, Andrea , Stevens, Robert David , Wynn, James Lawrence , Reuter‐Rice, Karin

Mayo Clinic

Critical Care Medicine | February 21, 2025 | Volume: 53 | Issue: 5 | Pages: e1045-e1054

10.1097/ccm.0000000000006595 | PMID 39982128 Get It

OBJECTIVES: To develop the first core Critical Care Data Dictionary (C2D2) with common data elements (CDEs) to characterize critical illness and injuries. DESIGN: Group consensus process using modified Delphi approach. SETTING: Electronic surveys and in-person meetings. SUBJECTS: A multidisciplinary workgroup of clinicians and researchers with expertise in the care of the critically ill and injured. INTERVENTIONS: The Delphi process was divided into domain and CDE portions with each composed of two item generation rounds and one item reduction/refinement rounds. Two in-person meetings augmented this process to facilitate review and consideration of the domains and by panel members. The final set of domains and CDEs was then reviewed by the group to meet the competing criteria of utility and feasibility, resulting in the core dataset. MEASUREMENTS AND MAIN RESULTS: The 23-member Delphi panel was provided 1833 candidate variables for potential dataset inclusion. The final dataset includes 226 patient-level CDCs in nine domains, which include anthropometrics and demographics (8), chronic comorbid illnesses (18), advanced directives (1), ICU diagnoses (61), diagnostic tests (42), interventions (27), medications (38), objective assessments (26), and hospital course and outcomes (5). Upon final review, 91% of the panel endorsed the CDCs as meeting criteria for a minimum viable data dictionary. Data elements cross the lifespan of neonate through adult patients. CONCLUSIONS: The resulting C2D2 provides a foundation to facilitate rapid collection, analyses, and dissemination of information necessary for research, quality improvement, and clinical practice to optimize critical care outcomes. Further work is needed to validate the effectiveness of the dataset in a variety of critical care settings.
Characteristics of Patients With the Arrhythmogenic Mitral Valve Prolapse Syndrome and Sudden Cardiac Arrest and Sustained Ventricular Arrhythmias
Chakrabarti, Apurba , Giudicessi, John R. , Delling, Francesca N. , Dixit, Shalini , Lee, Yoo Jin , Muser, Daniele , Magnani, Silvia , Wijngaarden, Aniek L. van , Miller, Marc A. , Gandhi, Jonathan, Font, Jonaz , Martins, Raphaël P. , McCaffrey, James A. , Chapagain, Himal , Mathew, Don , Kancharla, Krishna , Syed, Faisal F. , Abid, Ahad, Cerbin, Lukasz , Garg, Lohit , Natale, Andrea , Enríquez, Andrés , Bogun, Frank , Ackerman, Michael J. , Liang, Jackson J. , Ezzeddine, Fatima , Delling, Francesca N , Lee, Yoo Jin , Muser, Daniele , Magnani, Silvia , van Wijngaarden, Aniek , Marsan, Nina Ajmone , Trivieri, Maria G , Font, Jonaz , Martins, Raphael , McCaffrey, James A , Santangeli, Pasquale , Marchlinski, Francis E , Chapagain, Himal , Mathew, Don , Kancharla, Krishna , Syed, Faisal F , Abid, Ahad , Tzou, Wendy , Della Rocca, Domenico G , Natale, Andrea , Mohanty, Sanghamitra , Sheldon, Seth H. , Kuo, Ling , Haugaa, Kristina , Aabel, Eivind W , Enriquez, Andres , Maeda, Shingo , Deshmukh, Amrish , Ackerman, Michael J , Liang, Jackson , Ezzeddine, Fatima M. , Marsan, Nina Ajmone , Santangeli, Pasquale , Marchlinski, Francis E. , Tzou, Wendy S. , Rocca, Domenico G. Della , Haugaa, Kristina H. , Aabel, Eivind W. , Deshmukh, Amrish , Ghannam, Michael

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | February 20, 2025 | Volume: 18 | Issue: 3 | Pages: No page available

10.1161/circep.124.013099 | PMID 39973752 Get It

BACKGROUND: Patients with arrhythmogenic mitral valve prolapse syndrome are at increased risk for life-threatening ventricular arrhythmias, but studies have been limited by small sample sizes. We sought to assemble an international arrhythmogenic mitral valve prolapse syndrome registry to delineate the clinical, imaging, and treatment characteristics of patients with arrhythmogenic mitral valve prolapse syndrome who survived sudden cardiac arrest (SCA) or had sustained ventricular tachycardia (VT) or ventricular fibrillation. METHODS: In this descriptive registry, we characterized patients with arrhythmogenic mitral valve prolapse syndrome who survived SCA, sustained VT, or ventricular fibrillation. Deidentified data were abstracted locally and combined centrally. RESULTS: We included 148 patients who had SCA or VT/ventricular fibrillation. Patients had a mean age of 43.7±15.4 years; 68% were women, 73% had bileaflet prolapse, 65% had mitral annular disjunction, 67% had nonsustained VT, and 59% had inferolateral T-wave inversions. Syncope (n=54, 48%) and anterolateral T-wave inversion (n=26, 22%) were relatively common. Catheter ablation was performed in 50 (35%) patients for premature ventricular complexes and in 18 (17.7%) patients for VT. Sites of origin for arrhythmias were commonly in the papillary muscles, fascicles, mitral annulus, and inferior/inferolateral left ventricle. CONCLUSIONS: In this international descriptive registry of patients with arrhythmogenic mitral valve prolapse syndrome and SCA, patients were young, women, and had bileaflet mitral valve prolapse, mitral annular disjunction, inferolateral T-wave inversions, and nonsustained VT. A history of syncope and anterolateral T-wave inversions was relatively common in patients who survived SCA or sustained VT/ventricular fibrillation.
Antiplatelet and Anticoagulation Usage During Ultrasound-Guided Incisionless Thread Carpal Tunnel Release
Dean, K. , Smith, Brandon J. , Shin, Alexander Y. , Brault, Jeffrey S. , Dean, Kaylie P, Shin, Alexander Y , Brault, Jeffrey S

Mayo Clinic

HAND | February 20, 2025 | Volume: 21 | Issue: 3 | Pages: 425-429

10.1177/15589447251317237 | PMID 39976134 Get It

Background: Carpal tunnel syndrome (CTS) is the most common peripheral nerve entrapment syndrome. The thread carpal tunnel release (TCTR) is an incision-less ultrasound-guided approach to divide the transverse carpal ligament. This retrospective case series aims to identify and assess the bleeding risks associated with continuing anticoagulation or antiplatelet therapy during TCTR. Methods: Retrospective chart review with follow-up questionnaires/surveys. One hundred and fourteen adult patients who were using antiplatelet or anticoagulation medication underwent 164 TCTR procedures during 2018 to 2023 at a single institution (tertiary care hospital) from June 29, 2018, and August 11, 2023. A chart review was performed to identify patients on antiplatelets or anticoagulants at the time of the procedure and to determine if there were any adverse events associated with continuing or holding their antiplatelet or anticoagulant therapy. Results: There were no significant complications associated with continuing or holding anticoagulation or antiplatelet therapy during TCTR. Conclusions: Continuing antiplatelet therapy during TCTR appears safe. The decision to continue antiplatelet or anticoagulation therapy should be made on a case-by-case basis.
Primary Fixation and Cyclic Performance of Posterior Horn Medial Meniscus Root Repair With Knotless Adjustable Suture Anchor–Based Fixation: A Human Biomechanical Evaluation Over 100,000 Loading Cycles
Bachmaier, Samuel , Krych, Aaron J. , Smith, Patrick A. , Nuelle, Clayton W. , Müller, Peter E., Bedi, Asheesh , Krych, Aaron J , Wijdicks, Coen A.

Mayo Clinic

The American Journal of Sports Medicine | February 19, 2025 | Volume: 53 | Issue: 5 | Pages: 1093-1100

10.1177/03635465251317210 | PMID 39972533 Get It

Background: Recent biomechanical evidence for adjustable suture anchor (ASA)–based posterior medial meniscus root (PMMR) fixation has shown promising results compared with conventional transtibial pull-out repair (TPOR). However, ASA fixation has not been evaluated in human tissue to 100,000 cycles. Hypothesis: ASA repair would lead to increased primary fixation strength and less cyclic displacement than conventional TPORs. Study Design: Controlled laboratory study. Methods: A total of 32 human medial menisci were used, 8 of which were intact specimens and served as native controls. For the others, PMMR tears were created and repaired using 3 different techniques (n = 8 group). Two conventional PMMR repairs were prepared consisting of two No. 2 simple sutures (TSS) and two No. 2 sutures in a Mason-Allen (MA) configuration, all tied over a cortical button. The knotless ASA repair was fixed in MA with repair sutures tensioned at 120 N (MA-120). The repairs’ initial force, stiffness, and relief displacement from the tensioned state toward repair unloading (2 N) were measured after fixation. All repair constructs were loaded for 100,000 cycles, with displacement and stiffness measured, and finally were pulled to failure. Results: The TPORs demonstrated similar primary fixation and cyclic loading behavior except for initial cyclic displacement (cycle 10). The ASA repair provided a higher initial repair load ( P < .001) and stiffness ( P < .001) with relief displacement similar to conventional TPORs. Lower initial cyclic displacement ( P < .011; cycle 10) with overall higher repair stiffness ( P < .011) resulted in significantly lower displacement ( P < .001) throughout testing for ASA repair. Although both TPORs were completely loose after 100,000 cycles, the ASA repair achieved near-native dynamic meniscal stabilization. The TSS repair had lower overall ultimate load ( P < .001) and ultimate stiffness ( P < .023) compared with the ASA repair. All repairs had lower ultimate stiffness and loads than the native meniscus ( P < .001). Conclusion: The ASA repair resulted in improved primary PMMR fixation that was stiffer with less cyclic displacement than conventional TPORs and approached that of the human meniscal function after 100,000 load cycles in a cadaveric model. However, all repair techniques had lower ultimate strength than the native human PMMR. Clinical Relevance: Knotless ASA meniscus root fixation resulted in higher tissue compression and less displacement in a cadaveric model; however, future clinical series with surveillance imaging will define the overall significance of healing rates.
Spatially Resolved, Multiregion Proteomics for Prediction of Immunotherapy Outcome in Deficient Mismatch Repair Metastatic Colorectal Cancer
Saberzadeh-Ardestani, Bahar , Liu, Zhenglong , Stein, Mariam I. , Sherman, Will A., Trussoni, Christy E. , Abbott, Charles W. , Yan, Dongyao , Smith, Skyler , Shanmugam, Kandavel , Graham, Rondell P. , Levy, Joshua , Ördög, Tamás , Sherman, William , Sherman, Will A , Diallo, Alos , Levy, Joshua J , Ordog, Tamas , Sinicrope, Frank A , Graham, Rondell P , Smith, Skyler , Sinicrope, Frank A.

Mayo Clinic

Clinical Cancer Research | February 19, 2025 | Volume: 31 | Issue: 9 | Pages: 1783-1795

10.1158/1078-0432.ccr-24-0853 | PMID 39969975 Get It

Abstract Purpose: Digital proteomic profiling was performed to identify spatial context in relationship to patient response and survival after anti–PD-1 therapy in metastatic colorectal cancer. Experimental Design: Primary colorectal cancers with deficient mismatch repair from patients treated with anti–PD-1 antibodies were analyzed (N = 30) using digital spatial profiling (GeoMx nCounter). At the invasive margin, 71 proteins were profiled in 10 regions of interest/slide that were segmented into 3 compartments labeled with pan-cytokeratin (epithelia), CD45 (stromal cells), and SYTO13 (nuclei). In an independent cohort (n = 13), digital spatial profiling data and single-cell transcriptomic data were analyzed. Differential protein abundance, after Benjamini–Hochberg correction, was examined by clinical response and progression-free survival (PFS) using multivariable Cox regression. Results: Protein abundance varied significantly between epithelial and stromal compartments. Nonresponders to anti–PD-1 showed higher fibronectin and smooth muscle actin abundance in the epithelial compartment that was associated with significantly shorter PFS (adjusted HR: 6.49 and 4.52, respectively; P &lt; 0.05). In CD45+ stroma, increased expression of proteins related to T cells (CD3 and CD4), NK cells (CD56), antigen presentation (CD40), immune activation (CD27, ICOS), and apoptosis (GZMA) were found in responders (vs nonresponders) to anti–PD-1; each marker was significantly associated with longer patient PFS (0.02 &lt; adjusted HR &lt; 0.17; P &lt; 0.05). In a separate cohort, consistent results by compartment were found for fibronectin and CD56. Gene expression data revealed that fibronectin and smooth muscle actin were primarily derived from cancer-associated fibroblasts. Conclusions: Spatially resolved protein profiles within microenvironments of deficient mismatch repair colorectal cancers can influence patient response and survival after anti–PD-1, highlighting their potential clinical significance.
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Hansen, Doris K. , Peres, Lauren C. , Dima, Danai , Richards, Alicia, Shune, Leyla , Afrough, Aimaz , Midha, Shonali , Dhakal, Binod , Kocoglu, Mehmet H. , Atrash, Shebli , Ferreri, Christopher, Davis, James A. , Bhurtel, Jenny , Wagner, Charlotte B , Bansal, Radhika , Smith, Kinaya, Avila, Gabriel De, Purvey, Sneha , Hosoya, Hitomi , Mikkilineni, Lekha , Oswald, Laura B. , Gaballa, Mahmoud , Forsberg, Peter A. , Janakiram, Murali , Htut, Myo , Maringanti, Sireesha Asoori, Kalariya, Nilesh, Hashmi, Hamza , Sborov, Douglas W. , Khouri, Jack , Raza, Shahzad , Atanackovic, Djordje , Alsina, Melissa , Freeman, Ciara Louise , Voorhees, Peter M. , Anderson, Larry D. , Martin, Thomas, Patel, Krina K. , Sidana, Surbhi , Castaneda Puglianini, Omar , Davis, James A , Bhurtel, Evguenia , McGuirk, Joseph , Wagner, Charlotte , Bansal, Radhika , Lieberman-Cribbin, Alex , De Avila, Gabriel , Purvey, Sneha , Hosoya, Hitomi , Kaur, Gurbakhash , Herr, Megan M. , Janakiram, Murali , Reshef, Ran , Sborov, Douglas W , Anwer, Faiz , Khouri, Jack , Alsina, Melissa , Locke, Frederick L , Voorhees, Peter , Anderson, Larry D , Lin, Yi , Patel, Krina , Sidana, Surbhi , Dima, Danai , Kocoglu, Mehmet H , Raza, Shahzad , Atrash, Shebli , Hansen, Doris K , Dhakal, Binod , Puglianini, Omar Castañeda , McGuirk, Joseph P. , Costello, Patrick , Kaur, Gurbakhash , Pasvolsky, Oren , Reshef, Ran , Nadeem, Omar , Anwer, Faiz , Locke, Frederick L. , Richard, Shambavi , Lin, Yi

Mayo Clinic

Journal of Clinical Oncology | February 18, 2025 | Volume: 43 | Issue: 13 | Pages: 1597-1609

10.1200/jco-24-01730 | PMID 39965175 Get It

PURPOSE Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). We compare safety, efficacy, and survival among patients with RRMM treated with standard-of-care (SOC) ide-cel or cilta-cel. METHODS Data were from a retrospective chart review of patients with RRMM leukapheresed by December 31, 2022, with the intent to receive SOC ide-cel or cilta-cel at 19 institutions. An inverse probability of treatment weighting (IPTW) approach was used to compare outcomes by therapy type. RESULTS A total of 641 patients were leukapheresed by December 31, 2022, with ide-cel (n = 386) and cilta-cel (n = 255). Five hundred eighty-six patients were infused (n = 350 for ide-cel; n = 236 for cilta-cel) with a median follow-up of 12.6 and 13.0 months for ide-cel and cilta-cel, respectively. After IPTW, patient characteristics were well balanced. Cilta-cel was associated with higher likelihood of grade ≥3 cytokine release syndrome (CRS; odds ratio [OR], 6.80 [95% CI, 2.28 to 20.33]), infections (OR, 2.03 [95% CI, 1.41 to 2.92]), second primary malignancies (OR, 1.77 [95% CI, 0.89 to 3.56]), and delayed neurotoxicity (OR, 20.07 [95% CI, 4.46 to 90.20]). Cilta-cel was also associated with better treatment responses (≥complete response: OR, 2.42 [95% CI, 1.63 to 3.60]), longer progression-free survival (hazard ratio [HR], 0.48 [95% CI, 0.36 to 0.63]), and longer overall survival (HR, 0.67 [95% CI, 0.46 to 0.97]). No associations were observed between therapy type and immune effector cell–associated neurotoxicity syndrome, any CRS, severe cytopenia at days 30 and 90, or nonrelapse mortality. We observed consistent findings when repeating the analyses restricting the ide-cel cohort to patients infused during the same time period as Food and Drug Administration approval for cilta-cel (≥March 2022). CONCLUSION Cilta-cel demonstrated superior efficacy and survival, with higher incidence of certain toxicities, compared with ide-cel.
A phase Ib window of opportunity study of atezolizumab administered intravesically or direct injection in patients undergoing radical cystectomy for bladder cancer: Results of the single dose cohorts.
Oughton, Jamie B. , Whelan, Ruby Smith , Green, Angela , Hubbard, Rachel, Kennish, Steven, McCready, Dominic, Senior, Ethan R, Bowler, Helen, Kendall, Jessica , Collinson, Fiona , Catto, James W.F. , Lister-Whelan, Ruby , Hussain, Syed A. , Riaz, Irbaz Bin , Griffin, Jon

Mayo Clinic

Journal of Clinical Oncology | February 18, 2025 | Volume: 43 | Issue: 5_suppl | Pages: 773-773

10.1200/jco.2025.43.5_suppl.773 Get It

773 Background: BCG-unresponsive High-risk non-muscle invasive bladder cancer (HRNMIBC) tumours have an ominous prognosis and require effective, tolerable treatments. Uptake remains low for FDA approved agents (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln or N-803) due to toxicity concerns. We hypothesize direct intravesical administration of a PDL1 inhibitor could be effective with less systemic toxicity. However, it is unknown whether antibodies delivered via this route can reach tumor vasculature. INVEST is a phase Ib window of opportunity study investigating the safety and preliminary activity of passive instillation and direct injection of intravesical atezolizumab into the tumour/bladder wall. Methods: Eligible participants (ECOG performance status 0-2) are awaiting radical cystectomy (RC) for any stage urothelial cell carcinoma. Participants with muscle invasive bladder cancer, must be ineligible for/ refuse cisplatin based neo-adjuvant chemotherapy. Atezolizumab (600mg or 1200mg) is administered via direct injection into the tumour/bladder or by instillation into the bladder. The 3+3 design is utilised in the dose confirmation stages where participants receive either Single or Multiple (between 3 and 6) dose(s) of treatment before RC. Efficacy signals are derived from pathological complete response at RC and progression-free survival at 2 years. Primary endpoint, Dose confirmation stage: The number of dose-limiting toxicities (DLTs) observed from first dose of trial treatment to RC. Results: Enrolment began in May 2023. 13 participants were recruited to the single dose cohorts: 11 male, and 2 female. Age (Range; 43-86); median 70y, 9 NMIBC, 4 MIBC. 7 for direct injection (4 at 600mg and 3 at 1200mg dose) and 6 for passive instillation (3 at 600mg and 3 at 1200mg). Due to technical issues (syringe size) the first direct injection participant did not receive the full 600mg and were replaced. 12 participants received trial treatment as planned. There were no DLTs; 5 participants experienced non-trial treatment related SAEs (4 infections, 2 ileus, 2 renal impairment; 7/8 events occurred post-RC and all SAEs resolved). All participants underwent planned RC within the protocol stipulated timeline. Median time from last treatment to RC was18 days. 5 of 13 participants had downstaging of tumour in cystectomy specimen. Following independent Safety Review Committee review, recruitment is now open for the dose confirmation phase (Multiple 1200mg dose) in both treatment routes. Conclusions: Single dose atezolizumab treatment at a dose of 600mg and 1200mg in passive instillation and direct injection cohorts was well tolerated. Early efficacy data is encouraging. Multiple weekly doses of 1200mg in each treatment route are now being investigated within the INVEST trial. Clinical trial information: ISRCTN15842444 .